A. Muir

4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C

John G. McHutchison, Gregory T. Everson, Stuart C. Gordon et al. · Journal of Hepatology · 2008 · 54 citations

A Phase 2, Hepatology, Hepatitis C +9

11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS

J.-P. Bronowicki, Mitchell Davis, S. Flamm et al. · Journal of Hepatology · 2012 · 41 citations

In Prior Peginterferon/ribavirin, Antiviral Therapy, Virology +4

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

E. Läwitz, M. Rodriquez-Torres, Vinod K. Rustgi et al. · Journal of Hepatology · 2010 · 41 citations

Viral Hepatitis, Immunology, Antiviral Drug Development +7

[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C

John G. McHutchison, Gregory T. Everson, S. Gordon et al. · Journal of Hepatology · 2007 · 28 citations · Full text

A Phase 2, Study Of Telaprevir, Hepatitis C +8

Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens

Alessandra Mangia, E. Läwitz, Edward Gane et al. · Journal of Hepatology · 2018 · 18 citations

Long-term Follow-up, Hepatology, Hepatitis C +11